Načítá se...
The Anticipated Next Season of EGFR Inhibitors
EGFR-directed therapy in lung cancer is here to stay, with new drugs targeting T790M-mediated resistance coming quickly and the field continuing to advance. With greater access to sophisticated tools for interrogating both the somatic and germline genome, and with widespread acceptance of the scient...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4391775/ https://ncbi.nlm.nih.gov/pubmed/25795633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0086 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|